Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2850
-0.0100 (-3.39%)
Aug 6, 2025, 4:27 PM BST
-3.39%
Market Cap18.47M
Revenue (ttm)n/a
Net Income (ttm)-1.59M
Shares Out6.26B
EPS (ttm)-0.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume77,278,048
Average Volume79,467,652
Open0.2905
Previous Close0.2950
Day's Range0.2755 - 0.2957
52-Week Range0.1100 - 0.3800
Beta1.61
RSI52.93
Earnings DateSep 12, 2025

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer... [Read more]

Founded 2017
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.